ATRX and central nervous system cancer: Following this line of argument, our own study identified potential biomarkers of good prognosis (ATRX and others) that were more apparently frequent in gliomas with higher levels of H3-3B/H3.3, whereas some biomarkers of poor prognosis (PIK3CA) were more strongly associated with gliomas with low levels of H3-3B, suggesting that the H3.3 levels might be useful for the prognosis of low-grade tumors.